GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » EV-to-Revenue

Marksans Pharma (NSE:MARKSANS) EV-to-Revenue : 3.37 (As of May. 26, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Marksans Pharma's enterprise value is ₹70,729 Mil. Marksans Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹21,009 Mil. Therefore, Marksans Pharma's EV-to-Revenue for today is 3.37.

The historical rank and industry rank for Marksans Pharma's EV-to-Revenue or its related term are showing as below:

NSE:MARKSANS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.46   Med: 1.77   Max: 5.54
Current: 3.37

During the past 13 years, the highest EV-to-Revenue of Marksans Pharma was 5.54. The lowest was 0.46. And the median was 1.77.

NSE:MARKSANS's EV-to-Revenue is ranked worse than
64.75% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs NSE:MARKSANS: 3.37

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Marksans Pharma's stock price is ₹168.45. Marksans Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹46.64. Therefore, Marksans Pharma's PS Ratio for today is 3.61.


Marksans Pharma EV-to-Revenue Historical Data

The historical data trend for Marksans Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma EV-to-Revenue Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 0.46 1.38 1.11 1.39

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 1.39 2.16 2.19 3.43

Competitive Comparison of Marksans Pharma's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Marksans Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's EV-to-Revenue falls into.



Marksans Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Marksans Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=70729.033/21008.52
=3.37

Marksans Pharma's current Enterprise Value is ₹70,729 Mil.
Marksans Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹21,009 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma  (NSE:MARKSANS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Marksans Pharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=168.45/46.638
=3.61

Marksans Pharma's share price for today is ₹168.45.
Marksans Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.64.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines